Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Paul Bunn to Antineoplastic Combined Chemotherapy Protocols

This is a "connection" page, showing publications Paul Bunn has written about Antineoplastic Combined Chemotherapy Protocols.

 
Connection Strength
  
 
 
5.862
  
  1. Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 05; 20(3):148-160.e2.
    View in: PubMed
    Score: 0.367
  2. Bunn PA, Gaspar LE, Weyant MJ, Mitchell JD. Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. Cancer. 2016 Mar 01; 122(5):674-5.
    View in: PubMed
    Score: 0.297
  3. Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10; 30(32):3909-12.
    View in: PubMed
    Score: 0.238
  4. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6317-23.
    View in: PubMed
    Score: 0.180
  5. Bunn PA. Diseases desperate grown. J Natl Cancer Inst. 2008 Apr 16; 100(8):520-1.
    View in: PubMed
    Score: 0.174
  6. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60.
    View in: PubMed
    Score: 0.161
  7. Bunn PA. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer? Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):5919-20.
    View in: PubMed
    Score: 0.157
  8. Bunn PA. Platinums in lung cancer: sufficient or necessary? J Clin Oncol. 2005 May 01; 23(13):2882-3.
    View in: PubMed
    Score: 0.140
  9. Bunn P. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):5-11.
    View in: PubMed
    Score: 0.134
  10. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002 Sep 15; 20(18 Suppl):23S-33S.
    View in: PubMed
    Score: 0.118
  11. Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
    View in: PubMed
    Score: 0.116
  12. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P, Bunn PA. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res. 2002 Mar; 8(3):904-12.
    View in: PubMed
    Score: 0.114
  13. Bunn PA, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):87-94.
    View in: PubMed
    Score: 0.113
  14. Bunn PA. Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'. Ann Oncol. 2001 Oct; 12(10):1339-40.
    View in: PubMed
    Score: 0.111
  15. Bunn PA. [State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer]. Anticancer Drugs. 2001 Jul; 12 Suppl 3:S3-8.
    View in: PubMed
    Score: 0.109
  16. Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9.
    View in: PubMed
    Score: 0.103
  17. Bunn PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000 Apr; 117(4 Suppl 1):138S-143S.
    View in: PubMed
    Score: 0.100
  18. Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):e191-e204.
    View in: PubMed
    Score: 0.097
  19. Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3419-24.
    View in: PubMed
    Score: 0.097
  20. Bunn PA. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):25-30.
    View in: PubMed
    Score: 0.092
  21. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, P?rol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
    View in: PubMed
    Score: 0.089
  22. Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Semin Oncol. 1998 Aug; 25(4 Suppl 9):2-10.
    View in: PubMed
    Score: 0.089
  23. Bunn PA. Triplet chemotherapy combinations with new agents: is there a rationale? Semin Oncol. 1998 Aug; 25(4 Suppl 9):55-61.
    View in: PubMed
    Score: 0.089
  24. Bunn PA, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol. 2018 09 01; 36(25):2571-2574.
    View in: PubMed
    Score: 0.089
  25. Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs. 2017 11; 28(10):1086-1096.
    View in: PubMed
    Score: 0.085
  26. Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Bar?n AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 01; 13(1):134-138.
    View in: PubMed
    Score: 0.083
  27. Bunn PA, Kelly K. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-144-S12-148.
    View in: PubMed
    Score: 0.083
  28. Bunn PA. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-153-S12-162.
    View in: PubMed
    Score: 0.083
  29. Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23.
    View in: PubMed
    Score: 0.083
  30. Bunn PA, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997 Apr; 24(2 Suppl 7):S7-69-S7-74.
    View in: PubMed
    Score: 0.081
  31. Bunn PA. Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):9-15.
    View in: PubMed
    Score: 0.079
  32. Bunn PA, Kelly K. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1996 Dec; 23(6 Suppl 16):11-5.
    View in: PubMed
    Score: 0.079
  33. Bunn PA. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):18-25.
    View in: PubMed
    Score: 0.079
  34. Bunn PA. Future directions in therapeutic approaches for small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):136-8.
    View in: PubMed
    Score: 0.079
  35. Bunn PA, Kelly KL. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60.
    View in: PubMed
    Score: 0.073
  36. Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Aug; 22(4 Suppl 9):2-6.
    View in: PubMed
    Score: 0.072
  37. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995 Jul; 13(7):1632-41.
    View in: PubMed
    Score: 0.072
  38. Bunn PA, Kelly K. New treatment agents for advanced small cell and non-small cell lung cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):53-63.
    View in: PubMed
    Score: 0.071
  39. Scarborough HA, Bunn PA, DeGregori J. Personalized one-two punches for lung cancer. Cell Res. 2015 Mar; 25(3):269-70.
    View in: PubMed
    Score: 0.069
  40. Hirsch FR, Bunn PA, Herbst RS. "Companion diagnostics": has their time come and gone? Clin Cancer Res. 2014 Sep 01; 20(17):4422-4.
    View in: PubMed
    Score: 0.067
  41. Bunn P, Arriagada R, Choi N, Feld R, Gregor A, Jett J, Johnson B, Komaki R, Kristjansen P, Murray N, et al. Combined modality therapy in small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S25-8.
    View in: PubMed
    Score: 0.066
  42. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge R, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10; 29(26):3567-73.
    View in: PubMed
    Score: 0.055
  43. Pisters KM, Valli?res E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9.
    View in: PubMed
    Score: 0.050
  44. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7.
    View in: PubMed
    Score: 0.044
  45. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist. 2008; 13 Suppl 1:37-46.
    View in: PubMed
    Score: 0.043
  46. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.042
  47. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535.
    View in: PubMed
    Score: 0.039
  48. Bunn PA, Greco FA, Einhorn L. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol. 1986 Sep; 13(3 Suppl 3):45-53.
    View in: PubMed
    Score: 0.039
  49. Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May; 24(3):213-21.
    View in: PubMed
    Score: 0.038
  50. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 01; 24(13):2038-43.
    View in: PubMed
    Score: 0.038
  51. Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1685-97; discussion 1698-700, 1705.
    View in: PubMed
    Score: 0.037
  52. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
    View in: PubMed
    Score: 0.037
  53. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA, Taraseviciene-Stewart L. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides. 2005 Aug; 26(8):1288-91.
    View in: PubMed
    Score: 0.036
  54. Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Cancer Treat Rep. 1984 Dec; 68(12):1439-46.
    View in: PubMed
    Score: 0.035
  55. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37.
    View in: PubMed
    Score: 0.034
  56. Bunn PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004 Sep; 6(2):85-98.
    View in: PubMed
    Score: 0.034
  57. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA, Ettinger DS. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5439-46.
    View in: PubMed
    Score: 0.034
  58. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
    View in: PubMed
    Score: 0.034
  59. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023 Nov-Dec; 73(6):620-652.
    View in: PubMed
    Score: 0.031
  60. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TL, Piazza G, Klein-Szanto AJ, Pamukcu R, Alila H, Bunn PA, Thompson WJ. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003 May; 2(5):479-88.
    View in: PubMed
    Score: 0.031
  61. Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):341-3.
    View in: PubMed
    Score: 0.031
  62. Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104.
    View in: PubMed
    Score: 0.030
  63. Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022 10; 28(10):2155-2161.
    View in: PubMed
    Score: 0.030
  64. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8.
    View in: PubMed
    Score: 0.027
  65. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15; 59(24):6178-84.
    View in: PubMed
    Score: 0.024
  66. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May; 4(5):1087-100.
    View in: PubMed
    Score: 0.022
  67. Pisters KM, Kris MG, Bunn PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-41-S12-44.
    View in: PubMed
    Score: 0.021
  68. Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 02; 104:45-51.
    View in: PubMed
    Score: 0.020
  69. Bunn PA. Current therapy of small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):1-4.
    View in: PubMed
    Score: 0.020
  70. Bunn PA. Future directions in clinical research for lung cancer. Chest. 1994 Dec; 106(6 Suppl):399S-407S.
    View in: PubMed
    Score: 0.017
  71. Bunn PA. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol. 1994 Jun; 21(3 Suppl 6):49-59.
    View in: PubMed
    Score: 0.017
  72. Shepherd FA, Bunn PA, Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013; 339-46.
    View in: PubMed
    Score: 0.015
  73. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20; 30(18):2248-55.
    View in: PubMed
    Score: 0.014
  74. Hazuka MB, Bunn PA. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am Rev Respir Dis. 1992 Apr; 145(4 Pt 1):967-77.
    View in: PubMed
    Score: 0.014
  75. Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989 Dec 28; 321(26):1784-90.
    View in: PubMed
    Score: 0.012
  76. Bunn PA. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol. 1989 Aug; 16(4 Suppl 6):10-21.
    View in: PubMed
    Score: 0.012
  77. Bunn PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989 Apr; 16(2 Suppl 5):27-33.
    View in: PubMed
    Score: 0.012
  78. Bunn PA. Diagnostic factors in intermediate and high-grade lymphomas: pathologic, immunologic, and clinical. J Clin Oncol. 1988 Jul; 6(7):1073-5.
    View in: PubMed
    Score: 0.011
  79. Dziadziuszko R, Siemiatkowska A, Limon J, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. J Thorac Oncol. 2007 Jan; 2(1):91-2.
    View in: PubMed
    Score: 0.010
  80. Ihde DC, Deisseroth AB, Lichter AS, Bunn PA, Carney DN, Cohen MH, Veach SR, Makuch RW, Johnston-Early A, Abrams RA, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol. 1986 Oct; 4(10):1443-54.
    View in: PubMed
    Score: 0.010
  81. Seifter EJ, Bunn PA, Cohen MH, Makuch RW, Dunnick NR, Javadpour N, Bensimon H, Eddy JL, Minna JD, Ihde DC. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol. 1986 Sep; 4(9):1365-73.
    View in: PubMed
    Score: 0.010
  82. Batist G, Carney DN, Cowan KH, Veach SR, Gilliom M, Bunn PA, Ihde DC. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 1986 Jun; 4(6):982-6.
    View in: PubMed
    Score: 0.010
  83. Brooks BJ, Seifter EJ, Walsh TE, Lichter AS, Bunn PA, Zabell A, Johnston-Early A, Edison M, Makuch RW, Cohen MH, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol. 1986 Feb; 4(2):200-9.
    View in: PubMed
    Score: 0.009
  84. Johnson BE, Ihde DC, Bunn PA, Becker B, Walsh T, Weinstein ZR, Matthews MJ, Whang-Peng J, Makuch RW, Johnston-Early A, et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med. 1985 Sep; 103(3):430-8.
    View in: PubMed
    Score: 0.009
  85. Lichter AS, Bunn PA, Ihde DC, Cohen MH, Makuch RW, Carney DN, Johnston-Early A, Minna JD, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer. 1985 May 01; 55(9 Suppl):2163-75.
    View in: PubMed
    Score: 0.009
  86. Doyle LA, Ihde DC, Carney DN, Bunn PA, Cohen MH, Matthews MJ, Puffenbarger R, Cordes RS, Minna JD. Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C. Am J Clin Oncol. 1984 Dec; 7(6):719-24.
    View in: PubMed
    Score: 0.009
  87. Brower M, Ihde DC, Johnston-Early A, Bunn PA, Cohen MH, Carney DN, Makuch RW, Matthews MJ, Radice PA, Minna JD. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med. 1983 Dec; 75(6):993-1000.
    View in: PubMed
    Score: 0.008
  88. Brower M, Carney DN, Ihde DC, Eddy J, Bunn PA, Cohen MH, Pelsor FR, Matthews MJ, Minna JD. High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung. Cancer. 1983 Nov 15; 52(10):1778-82.
    View in: PubMed
    Score: 0.008
  89. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30.
    View in: PubMed
    Score: 0.005
  90. Lamb R, Gonzalez R, Myers A, Bunn P, Robinson W. Aggressive non-Hodgkin's lymphomas in AIDS: the University of Colorado experience. Am J Med Sci. 1990 Dec; 300(6):345-9.
    View in: PubMed
    Score: 0.003
  91. Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984 Apr; 10(4):515-39.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)